StocksMedium•8 November 2026•
1 min read
Vir Biotechnology Hepatitis Delta Trial Meets Primary Endpoint with 44% Response Rate
Key Facts
1The Phase 3 ECLIPSE 1 trial for Elebsiran and Tobevibart met its primary endpoint with a 44% response rate.
279% of treated patients reached the secondary endpoint of undetectable virus levels.
3The company plans an FDA submission in mid-2027 following further pivotal readouts.
Vir Biotechnology's Phase 3 ECLIPSE 1 trial for Elebsiran and Tobevibart met its primary endpoint with a 44% response rate. Mugglehead Investment Magazine reported that 79% of treated patients reached the secondary endpoint of undetectable virus levels, supporting the company's regulatory path for treating chronic hepatitis delta.
The company plans to submit an application for FDA approval in mid-2027 following further pivotal readouts. VIR closed at $12.21 on November 6, 2026, having traded between a day low of $11.3 and a high of $12.45 during that session.